


**Iris BioTechnologies Inc. (OTCPink: IRSB)**

5201 Great America Parkway  
Suite 320  
Santa Clara, CA 95054

Share Price	\$0.14
Volume	0
Shares Outstanding	21,368,011
Market Cap	\$2.88m
52 Week High	\$0.33
52 Week Low	\$0.04

as of 05/30/2018

**Overview**

Iris BioTechnologies Inc. (OTCBB:IRSB) is a life sciences company that provides you and your physicians the information to choose the best medical treatment regimen before the treatment begins. Iris enables precision healthcare and this is the future of medicine. Iris analyses the totality of who you are by looking at a combination of many things including your nucleic acids such as DNA and RNA as well as proteins, family medical history, life style, and environmental exposure. Iris offers the best approach to cancer treatment through actionable integration of molecular profiling with clinical decision making, precision analysis of potential cancer recurrence and chemotherapy effectiveness, along with matching to targeted therapies and therapies in clinical trials. The Iris Nano-Biochip™ product pipeline includes: CancerChip™, PrenatalChip™, NeuroChip™ (Alzheimer's and Parkinson diseases), MetabolicChip™ (Diabetes), CardioChip™, and Chips for veterinary, agricultural (e.g., biofuel development), environmental, and other applications. The Iris BioWindows™ artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research.

**Disclaimer**

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

**Management Team****Simon Chin, MBA**

President, CEO and Founder

**Ronald Mark Gemberling, MD, FACS**

Chief Medical Officer

**James LeBlanc, MBA**

Vice President, Operations

**Ralph Sinibaldi, Ph.D.**

Vice President, Product Development

**Grace Osborne, MBA**

Vice President, Business Development

**Scott M. Wheelwright, Ph.D.**

Director, Operations

**Wilhelm Schaser**

Director, Education

**Recent News**

Wednesday, October 18, 2017 - 06:00 AM

[Simon Chin, CEO of IRIS Wellness Labs and IRIS Biotechnologies, Spoke About DNA Testing at the Global Wellness Summit 2017 Where Wellness Moonshot Was Launched](#)

Monday, June 13, 2016 - 08:00 AM

[Iris Biotechnologies Announces That the Japanese Patent Office Has Issued a Notice of Allowance of Its Key Patent Application – Artificial Intelligence System for Genetic Analysis](#)

Monday, May 23, 2016 - 04:40 PM

[Iris BioTechnologies Announces Its BioWindows 3-Risk Scores System for Multi-Omic Analysis in the War Against Cancer and Other Diseases](#)

Wednesday, November 25, 2015 - 01:18 PM

[Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP](#)

Monday, March 30, 2015 - 01:28 PM

[Hanson McClain Filed False Reports With the Security and Exchange Commission Regarding Iris BioTechnologies](#)